Driving the cell cycle to cancer.

Area of Science:

• Molecular Biology
• Cell Biology
• Oncology

Background:

• Cell cycle progression depends on coordinated kinase activation, often involving cyclin binding.
• Key cyclin-dependent kinases (Cdks) like Cdk4, Cdk6, Cdk2, and Cdk1 are crucial for cell cycle transitions and checkpoint responses.
• Deregulation of these Cdks is common in human tumors.

Purpose of the Study:

• To analyze the in vivo roles of specific cyclin-dependent kinases (Cdks) in cell cycle regulation and cancer development.
• To generate and characterize gene-targeted mouse models with activated or defective Cdk alleles.
• To understand how Cdk deregulation contributes to tumorigenesis and to develop therapeutic strategies.

Main Methods:

• Generation of gene-targeted mice with specific Cdk mutations (e.g., Cdk4 knockout, Cdk4 R24C knock-in).
• Phenotypic analysis of mutant mice, including size, fertility, disease development (diabetes), and tumor formation.
• Assessment of susceptibility to carcinogenic treatments in genetically modified mice.

Main Results:

• Cdk4-deficient mice are viable but exhibit smaller size, infertility, and early-onset insulin-dependent diabetes.
• Mice with a Cdk4 R24C mutation (INK inhibitor-insensitive) develop a wide range of spontaneous tumors and increased susceptibility to carcinogens.
• These findings highlight the critical role of Cdk4 in normal physiology and its implication in cancer development.

Conclusions:

• Cdk4 plays essential roles beyond cell cycle control, impacting organismal size, fertility, and metabolic health.
• The Cdk4 R24C mutant mouse model effectively recapitulates Cdk deregulation-driven tumorigenesis.
• These mouse models are invaluable for elucidating Cdk-driven cancer mechanisms and for validating novel cancer therapeutics.